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Background: Hypertension and depression are both important risk factors for cardiovascular diseases. Nevertheless,
the association of blood pressure on and depression has not been completely established. This study aims to
analyze whether depression may influence the control of blood pressure in hypertensive individuals at high
cardiovascular risk.
Methods: Cross-sectional study, embedded within the PREDIMED clinical trial, of 5954 hypertensive patients with
high cardiovascular risk factor profiles. The relationship between blood pressure control and depression was analyzed.
A multivariate analysis (logistic and log-linear regression), adjusting for potential confounders (socio-demographic factors,
body mass index, lifestyle, diabetes, dyslipidemia, and antihypertensive treatment), was performed.
Results: Depressive patients, with and without antidepressant treatment, had better blood pressure control
(OR: 1.28, CI 95%: 1.06-1.55, and OR: 1.30, CI 95%: 1.03-1.65, respectively) than non-depressive ones. Regarding
blood pressure levels, systolic blood pressure values (mmHg) were found to be lower in both treated and
untreated depressive patients (Log coefficient Beta: −1.59, 95% CI: −0.50 to −2.69 and Log coefficient Beta: −3.49,
95% CI: −2.10 to −4.87, respectively).
Conclusions: Among hypertensive patients at high cardiovascular risk, the control of blood pressure was better in
those diagnosed with depression.
Trial registration: Unique identifier: ISRCTN35739639.
Keywords: Hypertension, Depression, Blood pressureBackground
High blood pressure is a key risk factor for cardiovascu-
lar disease (CVD) incidence [1-3]. Its prevalence is glo-
bally estimated to be around 40%, and it accounted for
approximately 7.5 million deaths in 2008 [1]. The latest
health statistics from the United States of America have
reported a hypertension prevalence of 33% among
adults, and within this population only 53% reached tar-
get levels recommended by guidelines [4]. In addition to* Correspondence: mamunoz.bcn.ics@gencat.cat
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article, unless otherwise stated.the classical risk factors, in the last decade the impact of
psychosocial determinants, such as educational level and
depression, has received increasing attention [5-7]. The
prevalence of depression has risen dramatically in recent
years; in fact, the World Health Organization (2012) re-
ported more than 350 million people suffering from this
condition worldwide [8]. Depression has been found to
coexist with CVD and its associated risk factors such as
hypertension, diabetes, overweight, and unhealthy life
styles (smoking and harmful alcohol consumption)
[7,9,10]. Evidence supporting the relationship between
depression and blood pressure (BP) is however, complex
and remains controversial [11-13]. In addition, evidence
addressing the relationship between depression and
hypertension control in hypertensive populations withd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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timal control of BP is an essential key to reduce the risk
level of cardiovascular diseases [3]. Since depression is an
additional cardiovascular risk factor as some antidepres-
sant medication may modify BP levels. The present study
was, therefore, aimed at determining the association of
depression and BP control in elderly hypertensive people
at high cardiovascular risk.
Methods
Study design and participants
Cross-sectional study using baseline data of hypertensive
participants at high cardiovascular risk from the PREDIMED
Study (Prevention with the Mediterranean diet). All details
of the PREDIMED study including enrollment, design,
population, methods, and main results have been de-
scribed elsewhere [14,15]. For the present work, all the
hypertensive individuals (N = 5954) from the 7447 PRE-
DIMED study participants were included. They fulfilled
at least 1 of the 2 following criteria: 1) men (55–80 years
old) and women (60–80 years old) with either type-2
diabetes or 2) three or more CVD risk factors (current
smoking, dyslipidemia, body mass index (BMI) > =25 kg/m2,
or family history of premature cardiovascular diseases).
Exclusion criteria included previous history of CVD or
other diseases such as food allergies, alcoholism, infection
or acute inflammation, physical or mental disability, and
those individuals taking part in any other clinical trial.
Participants’ data were collected from medical records,
clinical evaluation, and face to face interviews. Validated
questionnaires were administered in order to obtain
data on nutritional and physical activity habits [16-18].
Blood samples for laboratory tests were also obtained.
Details on collection and measurements have been pub-
lished elsewhere [13,14].
Ethical considerations
All participants signed an informed consent. The project
was conducted in accordance with the Declaration of
Helsinki and its subsequent amendments. The PREDIMED
study was approved by the Institutional Review Board of
Hospital Clinic (Barcelona, Spain), and registered in the
Current Controlled Trials (number: ISRCTN3573963,
http://www.controlled-trials.com/ISRCTN35739639).
End points
Control of blood pressure
BP was considered well-controlled when systolic and
diastolic blood pressure values (SBP, DBP) were below
140 mmHg and 90 mmHg, respectively, according to the
recommendations of the European guidelines on cardio-
vascular disease prevention in clinical practice [18]. Both
SBP and DBP were calculated based on the average of 4
measurements (two in the right arm and two in the left),taken in the primary care centers by well-trained pri-
mary care nurses. BP measures were assessed after a
suitable resting period (more than 5 minutes) in a sitting
position to avoid variability in the values due to patient
movement/displacement. For the measurement of BP,
a validated semiautomatic sphygmomanometer (Omron
HEM-705CP) with an appropriately sized cuff for the arm
of each participant was used. The determinations were
performed at two minute intervals. The mean of the
second and third measurement was recorded. When a
difference > 5 mm Hg between the two determinations
more than 5 mm Hg was detected the whole process
was repeated.Main independent variable
Depression
Diagnosis of depression was established at the visit of in-
clusion in the study, by face to face interview, and the in-
formation was further confirmed in the clinical records.
Participants were asked if some doctor had previously di-
agnosed them from depression. In Spain, the diagnosis of
depression is carried out both by psychiatrists and family
doctors. Usually, diagnostic is made following the American
Psychological Association clinical criteria (DSM-IV) and
those of the International Classification of Diseases (ICD)
related to Mental and Behavioral Disorders or other mental
health scales, included in the standardized health guidelines
from the Spanish Ministry of Health. Antidepressant treat-
ment was registered according to the patients’ self-reported
information and consulting at the clinical records. In
addition, participants were also asked whether they
had taken any antidepressants in the previous month.
They were finally classified as: no diagnosis of depression
(no previous diagnosis of depression and not taking anti-
depressants), untreated depression (diagnosis of depres-
sion and not taking any antidepressants), and treated
depression (diagnosis of depression and taking at least one
of the following: selective serotonin reuptake inhibitors,
non-selective monoamine reuptake inhibitors, monoamine
oxidase A inhibitors, antidepressants in combination with
psycholeptics, and other antidepressant agents). Partici-
pants were also asked about the time that had elapsed
from since their first diagnosis of depression which was
categorized as: ≤ 5 years, 6–10 years, and ≥ 11 years.Co-variables
The following co-variables were taken into consideration:
age, sex, anxiolytic or sedative treatment, comorbidity
(diabetes and dyslipidemia), and antihypertensive treat-
ment (angiotensin-converting-enzyme inhibitor (ACE in-
hibitors), diuretics, calcium channel blockers, angiotensin
II receptor antagonists, β-blockers, α-blockers, or other
antihypertensive drugs).
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Educational attainment, BMI, smoking habits, adherence
to the Mediterranean diet pattern, physical activity, and
alcohol intake were included in the analysis as they can
be correlated with both depression and BP control.
Statistical analysis
The descriptive analysis of categorical variables was
expressed as percentages and quantitative variables by
mean and standard deviation (SD). Bivariate analyses
included chi square tests and ANOVA F-test. A multivariateTable 1 Main characteristics of study population by depressio
Depression level
No depression Untreated
depression
T
dep
(N = 5027) (N = 569) (N
Characteristics of participants % %
Age (years)† 67.3 (6.2) 66.9(6.0) 6
Sex (Women) 56.0 79.8
Educational attainment
High level 7.6 4.9
Middle level 15.9 13.7
Low level 76.6 81.4
Antidepressant treatmenta — —
Antianxiety or sedative treatmentb 14.8 37.8
Body Mass Index( Kg/m2)† 30.1(3.8) 30.8(4.2) 3
Life styles
Smokingc 38.3 24.6
Low adherence to the MeDiet patternd 45.8 48.0
Sedentarye 35.0 44.6
High alcohol intake patternf 21.7 16.2
Hypertension comorbidity
Diabetesg 43.5 41.7
Dyslipidaemiah 73.7 76.4
Blood pressure
Optimal control of blood pressurei 26.5 33.9
Systolic blood pressure( mmHg)† 151.1(19.0) 147.8(18.9) 15
Diastolic blood pressure( mmHg)† 83.7(10.2) 83.1(10.0) 8
Antihypertensive treatmentj 80.6 85.8
aTaking at least one of the following drugs: Selective serotonin reuptake inhibitors,
antidepressants in combination with psycholeptics, others antidepressant agents.
bTaking at least one of the following drugs: benzodiazepine derivatives, azaspirode
antianxiety agents, ethanolamine derivatives, other anxiolytics, hypnotics and sedat
cCurrent smoker.
dAdherence to Mediterranean diet pattern < 9 points (median) on a scale of 0–14.
ePhysical activity in leisure time < 1000 kcal/week in last year.
fAlcohol consumption more than 20gr. daily in men and 10 gr. daily in women.
gDiagnosis of diabetes.
hDiagnosis of dyslipidaemia.
iSystolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg.
jTaking at least one of the following antihypertensive drugs: angiotensin-converting
angiotensin II receptor antagonists, Beta-blockers, α-blockers, or other antihyperten
†Mean - Standard Deviation, p - value: ANOVA F test.logistic model was fitted to evaluate the association and
estimate Odds Ratio (OR) between depression level and
length, and good BP control of blood pressure. To confirm
the association observed between well-controlled BP and
depression, continuous variables were adjusted by log-
linear regression for potential confounders (age, sex, edu-
cational attainment, anxyolitic or sedative treatment, BMI,
lifestyle, hypertension co-morbidity, and antihypertensive
treatment). Those statistically significant at bivariate ana-
lysis, or which could have any clinical relationship with
the final end-points, were included in the multivariaten and depression length
s Time with depression diagnostic
reated
ressiona
≤ 5 years 6-10 years ≥ 11 years
= 358) (N = 268) (N = 159) (N = 500)
% P-value % % P-value P-value
6.8(5.7) 0.137 66.4(6.0) 66.7(6.1) 67.1(5.8) 0.290
84.6 0.001 82.5 78.0 82.4 0.881
6.4 0.003 7.1 7.5 4.0 0.280
11.7 11.6 12.6 13.8
81.8 81.3 79.9 82.2
— — 45.9 37.7 35.0 0.004
61.5) 0.001 45.5 48.4 47.2 0.700
0.5(3.6) 0.001 30.5(4.0) 30.8(3.8) 30.8(4.0) 0.521
23.5 0.001 22.8 24.5 24.8 0.543
50.8 0.042 47.4 45.3 51.2 0.256
50.0 0.001 47.8 45.3 46.6 0.800
10.3 0.001 14.6 15.1 13.2 0.567
36.3 0.009 42.2 44.7 36.6 0.094
83.2 0.001 81.0 73.6 79.8 0.894
36.3 0.001 31.3 41.5 34.6 0.520
0.4(18.9) 0.001 146.1(17.0) 145.8(18.7) 146.7(18.9) 0.832
2.6(9.4) 0.052 83.7(9.6) 83.3(10.4) 82.3(9.6) 0.143
87.2 0.001 85.5 85.5 86.8 0.680
non-selective monoamine reuptake inhibitors, Monoamine oxidase A inhibitors,
canedione derivatives, GABA (gamma-aminobutyric acid) analogues, natural
ives agents.
-enzyme inhibitor (ACE inhibitors), diuretics, calcium channel blockers,
sive drugs.
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(CI) of 95% were employed for all statistical analyses. The
goodness-of-fit logistic models were performed using
Hosmer and Lemeshow test, and for linear model residual
validation the Kolmogorov test was used.
Results
Mean age of the participants was 67.2 years (SD 6.2),
60.5% were women, and 15.6% had depression. Amongst
this group 71% had had depression diagnosed more than
six years ago.
Bivariate analysis
Characteristics of participants according to depression
Depressive participants were more commonly women,
had low educational level, presented more obesity, and
were sedentary and dyslipidemic. In contrast, members
of this group were less frequently smokers and alcohol
drinkers. With respect to BP, depressive participants had
lower SBP and DBP values (Table 1). Participants with
treated depression had a higher percentage of BP control,
and a greater probability of receiving antihypertensive
treatment. The percentage of patients receiving antide-
pressants was higher in those diagnosed more recently
(less than 5 years).
Control of blood pressure
After adjusting for the main co-variables (age, sex, anti-
anxiety or sedative treatment, diabetes, dyslipidemia and
anti-hypertensive treatment) and potential confoundingFigure 1 Odds Ratios of optimal blood pressure control according to
indicate 95% confidence intervals and vertical line references OR = 1. Tx ind
depression is the reference category for the response variable.factors (educational levels, BMI, smoking, diet pattern,
and physical activity) depressive participants, with or
without antidepressants, more frequently presented well-
controlled BP than non-depressive ones (OR: 1.28, CI95%:
1.06-1.55 and OR: 1.30, CI95%: 1.03-1.65, respectively).
Participants whose depression had been previously diag-
nosed between six and ten years had better BP control
than the more recently diagnosed ones (OR: 1.62, CI95%:
1.07-2.45) (Figure 1). When considering BP as a continu-
ous variable, only SBP figures were significantly lower in
depressive patients, whilst DBP ones were unaffected
(Table 2). Women, younger participants, and lower BMI
were found to be related to better SBP and DBP levels.
Discussion
In the present study we found that depressive, hyperten-
sive participants at high cardiovascular risk had better
BP values.
Although depression is considered an independent risk
factor for hypertension incidence, and a number of au-
thors have found it related to higher BP levels [19-21],
its role in the control of BP values remains unclear [22].
Limited data have reported that hypertensive patients
taking antidepressants have lower blood pressure levels
[23]. One possible explanation for the effect of antide-
pressants on lowering blood pressure could be a reduc-
tion in vagal activity, decreased heart rate variability and
baroreflex sensitivity [24], and neuro-endocrine pathways
[25-29]. Our results concur with other studies performed
in general populations [12,13,24,30]. Research analyzing adepression level. Circles represent Odds Ratios, Horizontal lines
icates treatment and MeDiet indicates the Mediterranean Diet. No
Table 2 Log-linear model coefficients of systolic and diastolic blood pressure according to depression level and
adjusted co-variables
Natural logarithm of systolic blood pressure
(mmHg)†
Natural logarithm of diastolic blood pressure
(mmHg)‡
Coefficients§ Lower
CI 95%§
Upper
CI 95%§
P-value Coefficients§ Lower
CI 95%§
Upper
CI 95%§
P-value
Depression level
No Depression Ref Ref Ref Ref Ref Ref Ref Ref
Untreated depressiona −1.59 −2.69 −0.50 0.004 −0.59 −1.64 0.462 0.272
Treated depressionb −3.49 −4.87 −2.10 0.001 −0.85 −2.18 0.49 0.213
Anti-Anxiety or sedative treatmentc −0.82 −1.66 0.02 0.056 −0.18 −0.99 0.62 0.657
Age (years) 0.25 0.20 0.31 0.001 −0.37 −0.42 0-.32 0.001
Sex (Women) −2.60 −3.46 −1.75 0.001 −2.62 −3.44 −1.79 0.001
Educational attainment
High level Ref Ref Ref Ref Ref Ref Ref Ref
Middle level 0.96 −0.45 2.37 0.183 1.09 −0.27 2.44 0.117
Low level 0.13 −1.12 1.38 0.841 −0.42 −1.62 0.78 0.491
Body Mass Index( Kg/m2) 0.24 0.16 0.33 0.001 0.42 0.34 0.50 0.001
Smokingd −0.80 −1.65 0.05 0.064 −0.76 −1.57 0.05 0.067
Low adherence to the
MeDiet patterne
0.11 −0.56 0.78 0.746 −0.01 −0.65 0.64 0.989
Sedentaryf 0.17 −0.46 0.80 0.600 −0.07 −0.68 0.54 0.816
High alcohol intakeg 0.64 −0.17 1.45 0.122 0.72 −0.06 1.50 0.069
Diabetesh 1.28 0.62 1.94 0.001 −1.94 −2.57 −1.30 0.001
Dyslipidemiai −0.34 −0.34 0.41 0.370 −0.60 −1.31 0.12 0.104
Antihypertensive treatmentj 0.55 −0.26 1.37 0.182 0.46 −0.32 1.24 0.252
aDiagnosis of depression and not taking any antidepressant drugs.
bDiagnosis of depression and taking at least one of the following drugs: Selective serotonin reuptake inhibitors, non-selective monoamine reuptake inhibitors,
Monoamine oxidase A inhibitors, antidepressants in combination with psycholeptics, others antidepressant agents.
cTaking at least one of the following drugs: benzodiazepine derivatives, azaspirodecanedione derivatives, GABA (gamma-aminobutyric acid) analogues, natural
antianxiety agents, ethanolamine derivatives, other anxiolytics, hypnotics and sedatives agents.
dCurrent smoker.
eAdherence to Mediterranean diet pattern < 9 points (median) on a scale of 0–14.
fPhysical activity in leisure time < 1000 kcal/week in last year.
gAlcohol consumption more than 20gr. daily in men and 10 gr. daily in women.
hDiagnosis of diabetes.
iDiagnosis of dyslipidaemia.
jTaking at least one of the following antihypertensive drugs: angiotensin-converting-enzyme inhibitor (ACE inhibitors), diuretics, calcium channel blockers, angiotensin II
receptor antagonists, Beta-blockers, α-blockers, or other antihypertensive drugs.
†Kolmogorov-Smirnov Test (p value): 0.271.
‡Kolmogorov-Smirnov Test (p value): 0.56.
§Coefficients values multiplied by 100.
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hypertensive drugs has also shown that individuals with
episodes, or symptoms of depression, tended to have
lower SBP and DBP [31]. It is not clear whether depres-
sion is the cause or the consequence of differences in the
control of BP values [32,33]. Confounders related to both
hypertension and depression, such as physical activity,
low-fat diet, non-smoking, and alcohol intake, were
included in our analysis [34]. Some antidepressant,
anti-anxiety, and antipsychotic agents, either alone or
in combination with cardiovascular therapies including
antihypertensive drugs, have been reported to inducea drop in BP [35-37]. Our participants diagnosed with
depression, and those taking antidepressant treatments,
received more antihypertensive drugs. Nevertheless, the
association observed between depression and better blood
pressure values persisted after adjusting for this variable in
the multivariate analysis, which indicates that this associ-
ation may be independent, as has been shown in previous
studies [24,33].
It could be hypothesized, moreover, that the frequent
use of health services by depressive patients could contri-
bute to an accurate follow-up and good control of their
hypertension. The Spanish Health System guarantees a
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addition, family doctors have access to well-established
chronic care protocols, which ensure the better control
and follow-up of patients with co-morbidity (hypertension
and depression).
Implication of our results
Our findings indicate the relevance of performing a holis-
tic approach to the co-morbidity when tackling the care of
chronic patients attended in primary care. Preventions
among family physicians toward the use of antidepressants
in hypertensive patients with depression should be ad-
dressed individually since many studies have shown an
improvement in BP control.
Study limitations and strengths
The cross-sectional design of our study does not allow
causal inferences to be drawn. Future observational re-
search studies are needed to establish the role of psy-
chosocial factors in the good control of cardiovascular
risk factors and the prognosis of cardiovascular diseases,
especially in hypertensive individuals or those at high
cardiovascular risk.
For reasons of statistical power the different antide-
pressants were grouped together. It is possible that a lar-
ger sample could establish variations according to the
antidepressant analyzed. The time elapsed from the first
diagnosis of depression could not be used as a proxy for
the current prevalence of depression as the only way to
establish the current state of the disease is through the
prescription of antidepressants, and no specific tests
were conducted in the participants. We had information
about the family history of cardiovascular diseases his-
tory but none concerning about family history of depres-
sion and hypertension.
Conclusion
Among hypertensive patients at high cardiovascular risk,
blood pressure was better controlled in those diagnosed
with depression.
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